DDInter1003 DDInter1147
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Ixekizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ixekizumab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Ixekizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Ixekizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ixekizumab may lead to a major life threatening interaction when taken with Etanercept
Ixekizumab may lead to a major life threatening interaction when taken with Upadacitinib